O	0	10	Prevention
O	11	13	of
B-condition	14	21	cardiac
I-condition	22	33	dysfunction
O	34	40	during
O	41	49	adjuvant
O	50	56	breast
O	57	63	cancer
O	64	71	therapy
O	72	73	(
O	73	78	PRADA
O	78	79	)
O	79	80	:
O	81	82	a
O	83	84	2
O	85	86	×
O	87	88	2
O	89	98	factorial
O	98	99	,
O	100	110	randomized
O	110	111	,
O	112	119	placebo
O	119	120	-
O	120	130	controlled
O	130	131	,
O	132	138	double
O	138	139	-
O	139	144	blind
O	145	153	clinical
O	154	159	trial
O	160	162	of
B-intervention	163	174	candesartan
I-intervention	175	178	and
I-intervention	179	189	metoprolol
O	189	190	.

O	191	203	Contemporary
O	204	212	adjuvant
O	213	222	treatment
O	223	226	for
O	227	232	early
O	233	239	breast
O	240	246	cancer
O	247	249	is
O	250	260	associated
O	261	265	with
O	266	274	improved
O	275	283	survival
O	284	287	but
O	288	290	at
O	291	294	the
O	295	299	cost
O	300	302	of
O	303	312	increased
O	313	317	risk
O	318	320	of
O	321	335	cardiotoxicity
O	336	339	and
O	340	347	cardiac
O	348	359	dysfunction
O	359	360	.

O	361	363	We
O	364	370	tested
O	371	374	the
O	375	385	hypothesis
O	386	390	that
O	391	402	concomitant
O	403	410	therapy
O	411	415	with
O	416	419	the
O	420	431	angiotensin
O	432	440	receptor
O	441	448	blocker
O	449	460	candesartan
O	461	463	or
O	464	467	the
O	468	469	β
O	469	470	-
O	470	477	blocker
O	478	488	metoprolol
O	489	493	will
O	494	503	alleviate
O	504	507	the
O	508	515	decline
O	516	518	in
O	519	523	left
O	524	535	ventricular
O	536	544	ejection
O	545	553	fraction
O	554	555	(
O	555	559	LVEF
O	559	560	)
O	561	571	associated
O	572	576	with
O	577	585	adjuvant
O	585	586	,
O	587	600	anthracycline
O	600	601	-
O	601	611	containing
O	612	620	regimens
O	621	625	with
O	626	628	or
O	629	636	without
O	637	648	trastuzumab
O	649	652	and
O	653	662	radiation
O	662	663	.

O	664	666	In
O	667	668	a
O	669	670	2
O	671	672	×
O	673	674	2
O	675	684	factorial
O	684	685	,
O	686	696	randomized
O	696	697	,
O	698	705	placebo
O	705	706	-
O	706	716	controlled
O	716	717	,
O	718	724	double
O	724	725	-
O	725	730	blind
O	731	736	trial
O	736	737	,
O	738	740	we
O	741	749	assigned
B-total-participants	750	753	130
B-eligibility	754	759	adult
I-eligibility	760	765	women
I-eligibility	766	770	with
I-eligibility	771	776	early
I-eligibility	777	783	breast
I-eligibility	784	790	cancer
I-eligibility	791	794	and
I-eligibility	795	797	no
I-eligibility	798	805	serious
I-eligibility	806	808	co
I-eligibility	808	809	-
I-eligibility	809	818	morbidity
O	819	821	to
O	822	825	the
O	826	837	angiotensin
O	838	846	receptor
O	847	854	blocker
O	855	866	candesartan
O	867	876	cilexetil
O	876	877	,
O	878	881	the
O	882	883	β
O	883	884	-
O	884	891	blocker
O	892	902	metoprolol
O	903	912	succinate
O	912	913	,
O	914	916	or
O	917	925	matching
B-control	926	934	placebos
O	935	937	in
O	938	946	parallel
O	947	951	with
O	952	960	adjuvant
O	961	971	anticancer
O	972	979	therapy
O	979	980	.

O	981	984	The
O	985	992	primary
O	993	1000	outcome
O	1001	1008	measure
O	1009	1012	was
B-outcome-Measure	1013	1019	change
I-outcome-Measure	1020	1022	in
I-outcome-Measure	1023	1027	LVEF
O	1028	1030	by
O	1031	1038	cardiac
O	1039	1047	magnetic
O	1048	1057	resonance
O	1058	1065	imaging
O	1065	1066	.

O	1067	1068	A
O	1069	1075	priori
O	1075	1076	,
O	1077	1078	a
O	1079	1085	change
O	1086	1088	of
O	1089	1090	5
O	1091	1101	percentage
O	1102	1108	points
O	1109	1112	was
O	1113	1123	considered
O	1124	1134	clinically
O	1135	1144	important
O	1144	1145	.

O	1146	1151	There
O	1152	1155	was
B-outcome	1156	1158	no
I-outcome	1159	1170	interaction
I-outcome	1171	1178	between
I-outcome	1179	1190	candesartan
I-outcome	1191	1194	and
I-outcome	1195	1205	metoprolol
I-outcome	1206	1216	treatments
O	1217	1218	(
O	1218	1219	P
O	1220	1221	=
O	1222	1223	0
O	1223	1224	.
O	1224	1227	530
O	1227	1228	)
O	1228	1229	.

O	1230	1233	The
O	1234	1241	overall
O	1242	1249	decline
O	1250	1252	in
B-outcome	1253	1257	LVEF
O	1258	1261	was
B-cv-cont-mean	1262	1263	2
I-cv-cont-mean	1263	1264	.
I-cv-cont-mean	1264	1265	6
O	1266	1267	(
O	1267	1269	95
O	1269	1270	%
O	1271	1273	CI
O	1274	1275	1
O	1275	1276	.
O	1276	1277	5
O	1277	1278	,
O	1279	1280	3
O	1280	1281	.
O	1281	1282	8
O	1282	1283	)
O	1284	1294	percentage
O	1295	1301	points
O	1302	1304	in
O	1305	1308	the
O	1309	1316	placebo
O	1317	1322	group
O	1323	1326	and
B-iv-cont-mean	1327	1328	0
I-iv-cont-mean	1328	1329	.
I-iv-cont-mean	1329	1330	8
O	1331	1332	(
O	1332	1334	95
O	1334	1335	%
O	1336	1338	CI
O	1339	1340	-
O	1340	1341	0
O	1341	1342	.
O	1342	1343	4
O	1343	1344	,
O	1345	1346	1
O	1346	1347	.
O	1347	1348	9
O	1348	1349	)
O	1350	1352	in
O	1353	1356	the
O	1357	1368	candesartan
O	1369	1374	group
O	1375	1377	in
O	1378	1381	the
O	1382	1391	intention
O	1391	1392	-
O	1392	1394	to
O	1394	1395	-
O	1395	1400	treat
O	1401	1409	analysis
O	1410	1411	(
O	1411	1412	P
O	1412	1413	-
O	1413	1418	value
O	1419	1422	for
O	1423	1430	between
O	1430	1431	-
O	1431	1436	group
O	1437	1447	difference
O	1447	1448	:
O	1449	1450	0
O	1450	1451	.
O	1451	1454	026
O	1454	1455	)
O	1455	1456	.

O	1457	1459	No
O	1460	1466	effect
O	1467	1469	of
O	1470	1480	metoprolol
O	1481	1483	on
O	1484	1487	the
O	1488	1495	overall
O	1496	1503	decline
O	1504	1506	in
B-outcome	1507	1511	LVEF
O	1512	1515	was
O	1516	1524	observed
O	1524	1525	.

O	1526	1528	In
O	1529	1537	patients
O	1538	1545	treated
O	1546	1549	for
O	1550	1555	early
O	1556	1562	breast
O	1563	1569	cancer
O	1570	1574	with
O	1575	1583	adjuvant
O	1584	1597	anthracycline
O	1597	1598	-
O	1598	1608	containing
O	1609	1617	regimens
O	1618	1622	with
O	1623	1625	or
O	1626	1633	without
O	1634	1645	trastuzumab
O	1646	1649	and
O	1650	1659	radiation
O	1659	1660	,
O	1661	1672	concomitant
O	1673	1682	treatment
O	1683	1687	with
O	1688	1699	candesartan
O	1700	1708	provides
O	1709	1719	protection
O	1720	1727	against
O	1728	1733	early
O	1734	1741	decline
O	1742	1744	in
O	1745	1751	global
O	1752	1756	left
O	1757	1768	ventricular
O	1769	1777	function
O	1777	1778	.
